[{"edinetCode":"E00986","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":56.0,"averageTemporaryStaff":11.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":2264800.0,"sharesOwendPercent":0.3052,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":180.23,"equityRatio":0.39,"cashAndCashEquivalents":2522102000.0,"assets":3425900000.0,"currentAssets":3129030000.0,"fixedAsset":296869000.0,"tangibleFixedAssets":122851000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":174017000.0,"liabilities":2084458000.0,"currentLiabilities":234486000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":146088000.0,"fixedLiabilities":1849972000.0,"bonds":null,"convertibleBond":1519094000.0,"commercialPaper":null,"longTermDebts":329044000.0,"netAsset":1341441000.0,"capitalStock":1337033000.0,"capital":2271815000.0,"capitalSurplus":1304195000.0,"accumulatedEarnings":-2236987000.0,"treasuryStock":-1990000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":741525000.0,"costOfSales":326743000.0,"grossProfit":414782000.0,"sgaExpenses":1571714000.0,"salaryAndBenefit":80959000.0,"depreciationAndSGA":12887000.0,"RDExpenses":1239563000.0,"operatingIncome":-1156931000.0,"nonOperatingIncome":6198000.0,"nonOperatingExpenses":19622000.0,"interestExpense":2183000.0,"ordinaryProfit":-1170355000.0,"extraordinaryGain":null,"extraordinaryLoss":918445000.0,"incomeBeforeTax":-2088800000.0,"incomeTaxes":5667000.0,"netIncome":-2094467000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-2094467000.0,"comprehensiveIncome":-2094467000.0,"eps":-287.52,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-55886000.0,"depreciationAndCashflowFromOperatingActivities":182734000.0,"cashFlowFromInvestingActivities":-458490000.0,"cashFlowFromFinancialActivities":2145528000.0,"changesInCashAndCashEquivalents":1630186000.0,"列1":"asr","submitDate":"2017\/6\/30","stockCode":4570,"accountingYear":"第35期（自 平成28年４月１日 至 平成29年３月31日）","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00986","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1624,"settlementDate":"2022\/3\/31","submitterName":"株式会社免疫生物研究所","submitterNameEnglish":"Immuno-Biological Laboratories Co., Ltd.","submitterNameKana":"カブシキガイシャメンエキセイブツケンキュウジョ","location":"藤岡市中字東田１０９１番地１","industory":"医薬品","corporateNumber":8070000000000.0},{"edinetCode":"E00986","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":57.0,"averageTemporaryStaff":11.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":2430043.0,"sharesOwendPercent":0.2917,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":241.64,"equityRatio":0.611,"cashAndCashEquivalents":2450875000.0,"assets":3295015000.0,"currentAssets":2998213000.0,"fixedAsset":296801000.0,"tangibleFixedAssets":122274000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":174526000.0,"liabilities":1277237000.0,"currentLiabilities":302154000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":146088000.0,"fixedLiabilities":975083000.0,"bonds":null,"convertibleBond":790121000.0,"commercialPaper":null,"longTermDebts":182956000.0,"netAsset":2017777000.0,"capitalStock":2013369000.0,"capital":2636302000.0,"capitalSurplus":1668682000.0,"accumulatedEarnings":-2289625000.0,"treasuryStock":-1990000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":758286000.0,"costOfSales":281308000.0,"grossProfit":476978000.0,"sgaExpenses":525769000.0,"salaryAndBenefit":82237000.0,"depreciationAndSGA":null,"RDExpenses":173030000.0,"operatingIncome":-48791000.0,"nonOperatingIncome":6087000.0,"nonOperatingExpenses":6309000.0,"interestExpense":1804000.0,"ordinaryProfit":-49013000.0,"extraordinaryGain":null,"extraordinaryLoss":2926000.0,"incomeBeforeTax":-51940000.0,"incomeTaxes":697000.0,"netIncome":-52637000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-52637000.0,"comprehensiveIncome":-52637000.0,"eps":-7.01,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":73847000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-6278000.0,"cashFlowFromFinancialActivities":-138300000.0,"changesInCashAndCashEquivalents":-71226000.0,"列1":"asr","submitDate":"2018\/6\/29","stockCode":4570,"accountingYear":"第36期（自 平成29年４月１日 至 平成30年３月31日）","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00986","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1624,"settlementDate":"2022\/3\/31","submitterName":"株式会社免疫生物研究所","submitterNameEnglish":"Immuno-Biological Laboratories Co., Ltd.","submitterNameKana":"カブシキガイシャメンエキセイブツケンキュウジョ","location":"藤岡市中字東田１０９１番地１","industory":"医薬品","corporateNumber":8070000000000.0},{"edinetCode":"E00986","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":61.0,"averageTemporaryStaff":9.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":2121134.0,"sharesOwendPercent":0.2432,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":245.47,"equityRatio":0.717,"cashAndCashEquivalents":1491808000.0,"assets":2988314000.0,"currentAssets":2111776000.0,"fixedAsset":876537000.0,"tangibleFixedAssets":114019000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":762517000.0,"liabilities":842550000.0,"currentLiabilities":550422000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":108956000.0,"fixedLiabilities":292128000.0,"bonds":null,"convertibleBond":200000000.0,"commercialPaper":null,"longTermDebts":86000000.0,"netAsset":2145763000.0,"capitalStock":2141355000.0,"capital":2792510000.0,"capitalSurplus":1824890000.0,"accumulatedEarnings":-2474056000.0,"treasuryStock":-1990000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":781215000.0,"costOfSales":320925000.0,"grossProfit":460290000.0,"sgaExpenses":633971000.0,"salaryAndBenefit":91175000.0,"depreciationAndSGA":null,"RDExpenses":236668000.0,"operatingIncome":-173680000.0,"nonOperatingIncome":21569000.0,"nonOperatingExpenses":3636000.0,"interestExpense":1347000.0,"ordinaryProfit":-155747000.0,"extraordinaryGain":null,"extraordinaryLoss":8255000.0,"incomeBeforeTax":-164002000.0,"incomeTaxes":3317000.0,"netIncome":-167319000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-167319000.0,"comprehensiveIncome":-167319000.0,"eps":-19.82,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-243935000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-593279000.0,"cashFlowFromFinancialActivities":-126320000.0,"changesInCashAndCashEquivalents":-959067000.0,"列1":"asr","submitDate":"2019\/6\/28","stockCode":4570,"accountingYear":"第37期（自 2018年４月１日 至 2019年３月31日）","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00986","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1624,"settlementDate":"2022\/3\/31","submitterName":"株式会社免疫生物研究所","submitterNameEnglish":"Immuno-Biological Laboratories Co., Ltd.","submitterNameKana":"カブシキガイシャメンエキセイブツケンキュウジョ","location":"藤岡市中字東田１０９１番地１","industory":"医薬品","corporateNumber":8070000000000.0},{"edinetCode":"E00986","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.72,"cashAndCashEquivalents":null,"assets":2802656000.0,"currentAssets":1937900000.0,"fixedAsset":864755000.0,"tangibleFixedAssets":113781000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":750973000.0,"liabilities":781496000.0,"currentLiabilities":505968000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":88934000.0,"fixedLiabilities":275528000.0,"bonds":null,"convertibleBond":200000000.0,"commercialPaper":null,"longTermDebts":69500000.0,"netAsset":2021159000.0,"capitalStock":2016751000.0,"capital":2792510000.0,"capitalSurplus":1824890000.0,"accumulatedEarnings":-2598660000.0,"treasuryStock":-1990000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":113323000.0,"costOfSales":62522000.0,"grossProfit":50801000.0,"sgaExpenses":155282000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-104480000.0,"nonOperatingIncome":176000.0,"nonOperatingExpenses":23546000.0,"interestExpense":267000.0,"ordinaryProfit":-127850000.0,"extraordinaryGain":4390000.0,"extraordinaryLoss":237000.0,"incomeBeforeTax":-123698000.0,"incomeTaxes":905000.0,"netIncome":-124603000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-124603000.0,"comprehensiveIncome":-124603000.0,"eps":-14.28,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/8\/14","stockCode":4570,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00986","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1624,"settlementDate":"2022\/3\/31","submitterName":"株式会社免疫生物研究所","submitterNameEnglish":"Immuno-Biological Laboratories Co., Ltd.","submitterNameKana":"カブシキガイシャメンエキセイブツケンキュウジョ","location":"藤岡市中字東田１０９１番地１","industory":"医薬品","corporateNumber":8070000000000.0},{"edinetCode":"E00986","endDate":"2019\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":2116950.0,"sharesOwendPercent":0.2427,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.717,"cashAndCashEquivalents":1250324000.0,"assets":2630600000.0,"currentAssets":1786559000.0,"fixedAsset":844040000.0,"tangibleFixedAssets":113781000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":730258000.0,"liabilities":739421000.0,"currentLiabilities":479493000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":75820000.0,"fixedLiabilities":259927000.0,"bonds":null,"convertibleBond":200000000.0,"commercialPaper":null,"longTermDebts":53000000.0,"netAsset":1891179000.0,"capitalStock":1886771000.0,"capital":2792510000.0,"capitalSurplus":1824890000.0,"accumulatedEarnings":-2728640000.0,"treasuryStock":-1990000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":230873000.0,"costOfSales":121138000.0,"grossProfit":109734000.0,"sgaExpenses":319579000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":136024000.0,"operatingIncome":-209844000.0,"nonOperatingIncome":1499000.0,"nonOperatingExpenses":43981000.0,"interestExpense":502000.0,"ordinaryProfit":-252326000.0,"extraordinaryGain":4390000.0,"extraordinaryLoss":237000.0,"incomeBeforeTax":-248173000.0,"incomeTaxes":6410000.0,"netIncome":-254584000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-254584000.0,"comprehensiveIncome":-254584000.0,"eps":-29.18,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-163806000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-9178000.0,"cashFlowFromFinancialActivities":-67090000.0,"changesInCashAndCashEquivalents":-241483000.0,"列1":"q2r","submitDate":"2019\/11\/14","stockCode":4570,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00986","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1624,"settlementDate":"2022\/3\/31","submitterName":"株式会社免疫生物研究所","submitterNameEnglish":"Immuno-Biological Laboratories Co., Ltd.","submitterNameKana":"カブシキガイシャメンエキセイブツケンキュウジョ","location":"藤岡市中字東田１０９１番地１","industory":"医薬品","corporateNumber":8070000000000.0},{"edinetCode":"E00986","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.795,"cashAndCashEquivalents":null,"assets":2268056000.0,"currentAssets":1447499000.0,"fixedAsset":820556000.0,"tangibleFixedAssets":113781000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":706774000.0,"liabilities":459658000.0,"currentLiabilities":215571000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":70810000.0,"fixedLiabilities":244086000.0,"bonds":null,"convertibleBond":200000000.0,"commercialPaper":null,"longTermDebts":36500000.0,"netAsset":1808398000.0,"capitalStock":1803990000.0,"capital":2792510000.0,"capitalSurplus":1824890000.0,"accumulatedEarnings":-2811421000.0,"treasuryStock":-1990000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":389854000.0,"costOfSales":199977000.0,"grossProfit":189876000.0,"sgaExpenses":488678000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-298801000.0,"nonOperatingIncome":15287000.0,"nonOperatingExpenses":66698000.0,"interestExpense":723000.0,"ordinaryProfit":-350212000.0,"extraordinaryGain":20308000.0,"extraordinaryLoss":237000.0,"incomeBeforeTax":-330142000.0,"incomeTaxes":7222000.0,"netIncome":-337364000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-337364000.0,"comprehensiveIncome":-337364000.0,"eps":-38.67,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/2\/14","stockCode":4570,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00986","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1624,"settlementDate":"2022\/3\/31","submitterName":"株式会社免疫生物研究所","submitterNameEnglish":"Immuno-Biological Laboratories Co., Ltd.","submitterNameKana":"カブシキガイシャメンエキセイブツケンキュウジョ","location":"藤岡市中字東田１０９１番地１","industory":"医薬品","corporateNumber":8070000000000.0},{"edinetCode":"E00986","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":65.0,"averageTemporaryStaff":11.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":2114500.0,"sharesOwendPercent":0.227,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":208.97,"equityRatio":0.82,"cashAndCashEquivalents":974456000.0,"assets":2372989000.0,"currentAssets":1592990000.0,"fixedAsset":779999000.0,"tangibleFixedAssets":113781000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":666217000.0,"liabilities":424532000.0,"currentLiabilities":397762000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":66000000.0,"fixedLiabilities":26769000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":20000000.0,"netAsset":1948457000.0,"capitalStock":1946291000.0,"capital":3029041000.0,"capitalSurplus":2061421000.0,"accumulatedEarnings":-3142182000.0,"treasuryStock":-1990000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":576692000.0,"costOfSales":359355000.0,"grossProfit":217337000.0,"sgaExpenses":812696000.0,"salaryAndBenefit":97254000.0,"depreciationAndSGA":null,"RDExpenses":318353000.0,"operatingIncome":-595359000.0,"nonOperatingIncome":16524000.0,"nonOperatingExpenses":99928000.0,"interestExpense":932000.0,"ordinaryProfit":-678762000.0,"extraordinaryGain":20308000.0,"extraordinaryLoss":237000.0,"incomeBeforeTax":-658691000.0,"incomeTaxes":9433000.0,"netIncome":-668125000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-668125000.0,"comprehensiveIncome":-668125000.0,"eps":-76.0,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-608746000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":10818000.0,"cashFlowFromFinancialActivities":81195000.0,"changesInCashAndCashEquivalents":-517351000.0,"列1":"asr","submitDate":"2020\/6\/29","stockCode":4570,"accountingYear":"第38期（自 2019年４月１日 至 2020年３月31日）","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00986","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1624,"settlementDate":"2022\/3\/31","submitterName":"株式会社免疫生物研究所","submitterNameEnglish":"Immuno-Biological Laboratories Co., Ltd.","submitterNameKana":"カブシキガイシャメンエキセイブツケンキュウジョ","location":"藤岡市中字東田１０９１番地１","industory":"医薬品","corporateNumber":8070000000000.0},{"edinetCode":"E00986","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.814,"cashAndCashEquivalents":null,"assets":2232642000.0,"currentAssets":1477247000.0,"fixedAsset":755395000.0,"tangibleFixedAssets":113662000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":641732000.0,"liabilities":413260000.0,"currentLiabilities":383349000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":56000000.0,"fixedLiabilities":29910000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":23500000.0,"netAsset":1819382000.0,"capitalStock":1817216000.0,"capital":3029041000.0,"capitalSurplus":2061421000.0,"accumulatedEarnings":-3271257000.0,"treasuryStock":-1990000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":116598000.0,"costOfSales":58715000.0,"grossProfit":57883000.0,"sgaExpenses":159494000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-101611000.0,"nonOperatingIncome":2150000.0,"nonOperatingExpenses":28220000.0,"interestExpense":206000.0,"ordinaryProfit":-127681000.0,"extraordinaryGain":null,"extraordinaryLoss":118000.0,"incomeBeforeTax":-127800000.0,"incomeTaxes":1274000.0,"netIncome":-129074000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-129074000.0,"comprehensiveIncome":-129074000.0,"eps":-13.85,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/8\/14","stockCode":4570,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00986","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1624,"settlementDate":"2022\/3\/31","submitterName":"株式会社免疫生物研究所","submitterNameEnglish":"Immuno-Biological Laboratories Co., Ltd.","submitterNameKana":"カブシキガイシャメンエキセイブツケンキュウジョ","location":"藤岡市中字東田１０９１番地１","industory":"医薬品","corporateNumber":8070000000000.0},{"edinetCode":"E00986","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":2269692.0,"sharesOwendPercent":0.2437,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.817,"cashAndCashEquivalents":809908000.0,"assets":2099067000.0,"currentAssets":1364185000.0,"fixedAsset":734882000.0,"tangibleFixedAssets":113662000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":621219000.0,"liabilities":381206000.0,"currentLiabilities":353676000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":41000000.0,"fixedLiabilities":27529000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":22000000.0,"netAsset":1717861000.0,"capitalStock":1715695000.0,"capital":3029041000.0,"capitalSurplus":2061421000.0,"accumulatedEarnings":-3372777000.0,"treasuryStock":-1990000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":247962000.0,"costOfSales":122393000.0,"grossProfit":125569000.0,"sgaExpenses":303060000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":138986000.0,"operatingIncome":-177491000.0,"nonOperatingIncome":3762000.0,"nonOperatingExpenses":54189000.0,"interestExpense":435000.0,"ordinaryProfit":-227918000.0,"extraordinaryGain":null,"extraordinaryLoss":118000.0,"incomeBeforeTax":-228037000.0,"incomeTaxes":2558000.0,"netIncome":-230595000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-230595000.0,"comprehensiveIncome":-230595000.0,"eps":-24.75,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-129019000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-8970000.0,"cashFlowFromFinancialActivities":-23000000.0,"changesInCashAndCashEquivalents":-164548000.0,"列1":"q2r","submitDate":"2020\/11\/13","stockCode":4570,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00986","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1624,"settlementDate":"2022\/3\/31","submitterName":"株式会社免疫生物研究所","submitterNameEnglish":"Immuno-Biological Laboratories Co., Ltd.","submitterNameKana":"カブシキガイシャメンエキセイブツケンキュウジョ","location":"藤岡市中字東田１０９１番地１","industory":"医薬品","corporateNumber":8070000000000.0},{"edinetCode":"E00986","endDate":"2020\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.824,"cashAndCashEquivalents":null,"assets":1996568000.0,"currentAssets":1272989000.0,"fixedAsset":723578000.0,"tangibleFixedAssets":127122000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":596455000.0,"liabilities":351910000.0,"currentLiabilities":326120000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":26000000.0,"fixedLiabilities":25789000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":20500000.0,"netAsset":1644658000.0,"capitalStock":1642492000.0,"capital":3029041000.0,"capitalSurplus":2061421000.0,"accumulatedEarnings":-3445981000.0,"treasuryStock":-1990000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":414578000.0,"costOfSales":189836000.0,"grossProfit":224742000.0,"sgaExpenses":455426000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-230684000.0,"nonOperatingIncome":9344000.0,"nonOperatingExpenses":78506000.0,"interestExpense":606000.0,"ordinaryProfit":-299846000.0,"extraordinaryGain":null,"extraordinaryLoss":118000.0,"incomeBeforeTax":-299965000.0,"incomeTaxes":3833000.0,"netIncome":-303799000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-303799000.0,"comprehensiveIncome":-303799000.0,"eps":-32.61,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/2\/12","stockCode":4570,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00986","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1624,"settlementDate":"2022\/3\/31","submitterName":"株式会社免疫生物研究所","submitterNameEnglish":"Immuno-Biological Laboratories Co., Ltd.","submitterNameKana":"カブシキガイシャメンエキセイブツケンキュウジョ","location":"藤岡市中字東田１０９１番地１","industory":"医薬品","corporateNumber":8070000000000.0},{"edinetCode":"E00986","endDate":"2021\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":65.0,"averageTemporaryStaff":9.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":2448800.0,"sharesOwendPercent":0.2629,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":174.7,"equityRatio":0.885,"cashAndCashEquivalents":552022000.0,"assets":1838038000.0,"currentAssets":1124969000.0,"fixedAsset":713069000.0,"tangibleFixedAssets":127122000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":585946000.0,"liabilities":208756000.0,"currentLiabilities":145008000.0,"shorTermDept":20000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":11000000.0,"fixedLiabilities":63748000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":59000000.0,"netAsset":1629282000.0,"capitalStock":1627116000.0,"capital":3029041000.0,"capitalSurplus":2061421000.0,"accumulatedEarnings":-3461357000.0,"treasuryStock":-1990000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":602749000.0,"costOfSales":255894000.0,"grossProfit":346855000.0,"sgaExpenses":587840000.0,"salaryAndBenefit":91654000.0,"depreciationAndSGA":null,"RDExpenses":267111000.0,"operatingIncome":-240984000.0,"nonOperatingIncome":22169000.0,"nonOperatingExpenses":91695000.0,"interestExpense":749000.0,"ordinaryProfit":-310511000.0,"extraordinaryGain":null,"extraordinaryLoss":118000.0,"incomeBeforeTax":-310630000.0,"incomeTaxes":8197000.0,"netIncome":-318827000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-318827000.0,"comprehensiveIncome":-318827000.0,"eps":-34.23,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-194145000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-17233000.0,"cashFlowFromFinancialActivities":-216000000.0,"changesInCashAndCashEquivalents":-422434000.0,"列1":"asr","submitDate":"2021\/6\/30","stockCode":4570,"accountingYear":"第39期（自 2020年４月１日 至 2021年３月31日）","accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00986","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1624,"settlementDate":"2022\/3\/31","submitterName":"株式会社免疫生物研究所","submitterNameEnglish":"Immuno-Biological Laboratories Co., Ltd.","submitterNameKana":"カブシキガイシャメンエキセイブツケンキュウジョ","location":"藤岡市中字東田１０９１番地１","industory":"医薬品","corporateNumber":8070000000000.0},{"edinetCode":"E00986","endDate":"2021\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.888,"cashAndCashEquivalents":null,"assets":1707152000.0,"currentAssets":1020031000.0,"fixedAsset":687120000.0,"tangibleFixedAssets":120081000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":567038000.0,"liabilities":188609000.0,"currentLiabilities":127039000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":6000000.0,"fixedLiabilities":61570000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":57500000.0,"netAsset":1518542000.0,"capitalStock":1516376000.0,"capital":3029041000.0,"capitalSurplus":2061421000.0,"accumulatedEarnings":-3572097000.0,"treasuryStock":-1990000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":125150000.0,"costOfSales":59479000.0,"grossProfit":65671000.0,"sgaExpenses":139565000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-73893000.0,"nonOperatingIncome":4932000.0,"nonOperatingExpenses":32679000.0,"interestExpense":40000.0,"ordinaryProfit":-101640000.0,"extraordinaryGain":null,"extraordinaryLoss":7041000.0,"incomeBeforeTax":-108681000.0,"incomeTaxes":2058000.0,"netIncome":-110740000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-110740000.0,"comprehensiveIncome":-110740000.0,"eps":-11.89,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/8\/13","stockCode":4570,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00986","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1624,"settlementDate":"2022\/3\/31","submitterName":"株式会社免疫生物研究所","submitterNameEnglish":"Immuno-Biological Laboratories Co., Ltd.","submitterNameKana":"カブシキガイシャメンエキセイブツケンキュウジョ","location":"藤岡市中字東田１０９１番地１","industory":"医薬品","corporateNumber":8070000000000.0},{"edinetCode":"E00986","endDate":"2021\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":2550773.0,"sharesOwendPercent":0.2739,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.818,"cashAndCashEquivalents":546335000.0,"assets":1745360000.0,"currentAssets":1088682000.0,"fixedAsset":656678000.0,"tangibleFixedAssets":120081000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":536596000.0,"liabilities":315411000.0,"currentLiabilities":215079000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":6000000.0,"fixedLiabilities":100332000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":96000000.0,"netAsset":1429948000.0,"capitalStock":1427782000.0,"capital":3029041000.0,"capitalSurplus":2061421000.0,"accumulatedEarnings":-3660690000.0,"treasuryStock":-1990000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":253993000.0,"costOfSales":129204000.0,"grossProfit":124789000.0,"sgaExpenses":261310000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":98086000.0,"operatingIncome":-136520000.0,"nonOperatingIncome":5700000.0,"nonOperatingExpenses":57349000.0,"interestExpense":132000.0,"ordinaryProfit":-188170000.0,"extraordinaryGain":null,"extraordinaryLoss":7041000.0,"incomeBeforeTax":-195211000.0,"incomeTaxes":4121000.0,"netIncome":-199333000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-199333000.0,"comprehensiveIncome":-199333000.0,"eps":-21.4,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-99503000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-39000000.0,"cashFlowFromFinancialActivities":132000000.0,"changesInCashAndCashEquivalents":-5687000.0,"列1":"q2r","submitDate":"2021\/11\/12","stockCode":4570,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00986","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1624,"settlementDate":"2022\/3\/31","submitterName":"株式会社免疫生物研究所","submitterNameEnglish":"Immuno-Biological Laboratories Co., Ltd.","submitterNameKana":"カブシキガイシャメンエキセイブツケンキュウジョ","location":"藤岡市中字東田１０９１番地１","industory":"医薬品","corporateNumber":8070000000000.0},{"edinetCode":"E00986","endDate":"2021\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.807,"cashAndCashEquivalents":null,"assets":1715442000.0,"currentAssets":980688000.0,"fixedAsset":734754000.0,"tangibleFixedAssets":120081000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":614672000.0,"liabilities":331842000.0,"currentLiabilities":221208000.0,"shorTermDept":125000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":4008000.0,"fixedLiabilities":110633000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":105992000.0,"netAsset":1383600000.0,"capitalStock":1383600000.0,"capital":3029041000.0,"capitalSurplus":2061421000.0,"accumulatedEarnings":-3704873000.0,"treasuryStock":-1990000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":448082000.0,"costOfSales":200596000.0,"grossProfit":247485000.0,"sgaExpenses":384163000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-136678000.0,"nonOperatingIncome":8049000.0,"nonOperatingExpenses":104272000.0,"interestExpense":378000.0,"ordinaryProfit":-232900000.0,"extraordinaryGain":2537000.0,"extraordinaryLoss":7041000.0,"incomeBeforeTax":-237404000.0,"incomeTaxes":6110000.0,"netIncome":-243515000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-243515000.0,"comprehensiveIncome":-243515000.0,"eps":-26.14,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2022\/2\/14","stockCode":4570,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00986","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":1624,"settlementDate":"2022\/3\/31","submitterName":"株式会社免疫生物研究所","submitterNameEnglish":"Immuno-Biological Laboratories Co., Ltd.","submitterNameKana":"カブシキガイシャメンエキセイブツケンキュウジョ","location":"藤岡市中字東田１０９１番地１","industory":"医薬品","corporateNumber":8070000000000.0}]